Fluvoxamine for Children and Adolescents With Obsessive-Compulsive Disorder: A Randomized, Controlled, Multicenter Trial

Riddle, Mark A.; Reeve, Elizabeth A.; Yaryura-Tobias, José A.; Yang, Hongqin; Claghorn, James L.; Gaffney, Gary R.; Greist, John H.; Holland, D.; McConville, Brian J.; Pigott, Teresa A.; Walkup, John T.

doi:10.1097/00004583-200102000-00017

Cited by 342 publications

(125 citation statements)

References 19 publications

Supporting

Mentioning

122

Contrasting

Unclassified

Order By: Relevance

“…In a small study, which was probably underpowered, fluvoxamine was significantly better than placebo on only two of three measures of improvement in obsessive-compulsive symptoms ). In the treatment of children and adolescents, the efficacy of fluvoxamine could also be shown in DBPC studies (Riddle et al 1996(Riddle et al , 2001) (A). Á Fluoxetine was superior to placebo in doubleblind studies Tollefson et al 1994;Zitterl et al 1999).…”

Section: Selective Serotonin Reuptake Inhibitors (Ssris)mentioning

confidence: 99%

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders – First Revision

Bandelow

Zohar

Hollander

et al. 2008

The World Journal of Biological Psychiatry

718

410

View full text Add to dashboard Cite

In this report, which is an update of a guideline published in 2002 (Bandelow et al. 2002, recommendations for the pharmacological treatment of anxiety disorder, obsessive-compulsive disorder (OCD) and post-traumatic stress disorder (PTSD) are presented. Since the publication of the first version of this guideline, a substantial number of new randomized controlled studies of anxiolytics have been published. In particular, more relapse prevention studies are now available that show sustained efficacy of anxiolytic drugs. The recommendations, developed by the World Federation of Societies of Biological Psychiatry (WFSBP) Task Force for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders, a consensus panel of 30 international experts, are now based on 510 published randomized, placebo-or comparator-controlled clinical studies (RCTs) and 130 open studies and case reports. First-line treatments for these disorders are selective serotonin reuptake inhibitors (SSRIs), serotonin-noradrenaline reuptake inhibitors (SNRIs) and the calcium channel modulator pregabalin. Tricyclic antidepressants (TCAs) are equally effective for some disorders, but many are less well tolerated than the SSRIs/ SNRIs. In treatment-resistant cases, benzodiazepines may be used when the patient does not have a history of substance abuse disorders. Potential treatment options for patients unresponsive to standard treatments are described in this overview. Although these guidelines focus on medications, non-pharmacological were also considered. Cognitive behavioural therapy (CBT) and other variants of behaviour therapy have been sufficiently investigated in controlled studies in patients with anxiety disorders, OCD, and PTSD to support them being recommended either alone or in combination with the above medicines.

show abstract

Section: Selective Serotonin Reuptake Inhibitors (Ssris)mentioning

confidence: 99%

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders – First Revision

Bandelow

Zohar

Hollander

et al. 2008

The World Journal of Biological Psychiatry

718

410

View full text Add to dashboard Cite

show abstract

“…These trials are of variable quality, but they include several large methodologically sound studies and it seems reasonable to conclude that the SSRIs are both safe and efficacious in the short-term treatment of paediatric OCD ( March et al, 1998;Geller et al, 2001;Riddle et al, 2001). The time taken to respond to treatment varies between the studies and, even though Riddle et al reported significant responses after only 1 week of treatment, most authors suggest titration over 6 to 8 weeks to maximum doses in partial or non-responders.…”

Section: Obsessive-compulsive Disordermentioning

confidence: 99%

Current issues in child and adolescent psychopharmacology. Part 2: Anxiety and obsessive—compulsive disorders, autism, Tourette's and schizophrenia

Coghill¹

2003

Adv. psychiatr. treat

View full text Add to dashboard Cite

This paper reviews the evidence base supporting the use of pharmacological treatments for child and adolescent psychiatric disorders. Recent advances in knowledge are highlighted, with some of the controversies. New evidence supports a role for selective serotonin reuptake inhibitors in the treatment of anxiety disorders and obsessive–compulsive disorder. Educational and behavioural approaches remain the mainstay of treatment for children and adolescents with autism, but there is evidence that adjunctive medication may be effective. Atypical antipsychotics have been investigated in the treatment of Tourette syndrome and early-onset schizophrenia. Many questions remain unanswered and further research is needed in all areas of paediatric psychopharmacology.

show abstract

“…Indeed, the response rates in the present study were quite low for both CGI-I (RIL ¼ 7%, PLA ¼ 7%) and CY-BOCS (RIL ¼ 16%, PLA ¼ 18%). Depending on the response criteria, other studies in pediatric OCD have found response rates greater than 25% (Liebowitz et al, 2002;March et al, 1998;Riddle et al, 2001). One study found that 4% of the placebo group achieved a score of o10 on the CY-BOCS (Pediatric OCD Treatment Study, 2004), a criterion met by no members of PLA in the current study.…”

Section: Discussionmentioning

confidence: 71%

12-Week, Placebo-Controlled Trial of Add-on Riluzole in the Treatment of Childhood-Onset Obsessive–Compulsive Disorder

Grant

Joseph

Farmer

et al. 2013

Neuropsychopharmacol

View full text Add to dashboard Cite

Many children with childhood-onset obsessive-compulsive disorder (OCD) fail to respond adequately to standard therapies. Evidence from preclinical and clinical studies suggests that the glutamatergic neurotransmitter system might be an alternative treatment target. This study examined the efficacy of riluzole, a glutamatergic modulator, as an adjunctive therapy for children with treatment-resistant OCD. In a 12-week, double-blind, placebo-controlled study, 60 treatment-resistant children and adolescents (mean age ¼ 14.5±2.4 years), with moderate to severe OCD (mean Children's Yale-Brown Obsessive-Compulsive Scale (CY-BOCS) ¼ 28.2 ± 3.7), 17 of whom also had concomitant autism spectrum disorder, were randomized to receive riluzole (final dose of 100 mg/day) or placebo in addition to the existing treatment regimen. Fifty-nine subjects completed the randomized trial. Primary outcome measures were changes on the CY-BOCS, the Clinical Global Impressions Scale, and the Children's Global Assessment Scale. Riluzole was fairly well tolerated, although it was associated with one case of pancreatitis and five instances of slight increases in transaminases. All subjects showed significant reductions in CY-BOCS scores during treatment; however, there was no significant difference between placebo and riluzole on any of the primary or secondary outcome measures. The study failed to demonstrate superiority of riluzole over placebo as an adjunctive treatment for children with childhood-onset OCD. However, future studies may show benefits for less treatment-refractory children with fewer concomitant medications.

show abstract

Fluvoxamine for Children and Adolescents With Obsessive-Compulsive Disorder: A Randomized, Controlled, Multicenter Trial

Cited by 342 publications

References 19 publications

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders – First Revision

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders – First Revision

Current issues in child and adolescent psychopharmacology. Part 2: Anxiety and obsessive—compulsive disorders, autism, Tourette's and schizophrenia

12-Week, Placebo-Controlled Trial of Add-on Riluzole in the Treatment of Childhood-Onset Obsessive–Compulsive Disorder

Contact Info

Product

Resources

About